Genesis Research Group

On Tuesday, 6 October 2026, Genesis Research Group's evidence synthesis, HEOR, and evidence planning teams will be presenting a webinar in partnership with online real-world evidence and HEOR research hub The Evidence Base. The topic of the webinar is 'Fr

Quick answer: What makes real-world evidence regulatory-grade? Regulatory-grade real-world evidence (RWE) is evidence generated from real-world data (RWD) in a way that can withstand regulatory, HTA, or payer scrutiny. It is not created by using a large o

First published: 11 October 2023 Updated: 21 September 2026 The FDA accepts real-world evidence (RWE) in regulatory decision-making for drugs, biologics, and medical devices, but only when the underlying real-world data (RWD) source has been evaluated as

11 August 2026 - Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company's global real-world evidence (RWE) and health economics

Methodological & Statistical Research This poster compares anchored and unanchored matching-adjusted indirect comparisons (MAICs) using Phase III trial data in moderate-to-severe ulcerative colitis. The analysis evaluated how each approach influences esti

Health Technology Assessment As the Kingdom of Saudi Arabia (KSA) implements new health technology assessment (HTA) requirements, understanding how economic evaluations may influence future pricing and reimbursement decisions is becoming increasingly impo

Organizational Practices As AI becomes increasingly integrated into healthcare decision-making, understanding payer expectations is critical. This poster explores US payer perspectives on drug manufacturer readiness for AI, finding that while payers are r

Methodological & Statistical Research In oncology HEOR, the methodological choices behind a cost-effectiveness estimate can shape decisions long before mature clinical data are available. This poster presents a modular oncology reference model for early e

Methodological & Statistical Research Looking back and pressure-testing the assumptions behind oncology cost-effectiveness evaluations. This poster reviews how ICER selected survival-extrapolation curves across oncology assessments between 2016 and 2025.